Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.

In previous studies we showed that a recombinant Modified Vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR-/-) against challenge. We continued these studies and determined, in the IFNAR-/- mouse model, whether the antibody responses induced by MVA-VP2 vaccination play a key role in protection against AHSV. Thus, groups of mice were vaccinated with wild type MVA (MVA-wt) or MVA-VP2 and the antisera from these mice were used in a passive immunisation experiment. Donor antisera from (a) MVA-wt; (b) MVA-VP2 vaccinated; or (c) MVA-VP2 vaccinated and AHSV infected mice, were transferred to AHSV non-immune recipient mice. The recipients were challenged with virulent AHSV together with MVA-VP2 vaccinated and MVA-wt vaccinated control animals and the levels of protection against AHSV-4 were compared between all these groups. The results showed that following AHSV challenge, mice that were passively immunised with MVA-VP2 vaccinated antisera were highly protected against AHSV disease and had lower levels of viraemia than recipients of MVA-wt antisera. Our study indicates that MVA-VP2 vaccination induces a highly protective humoral immune response against AHSV.

• Publication year

  2014

• Venue

  Virus Research

• Publication date

  2014-02-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.virusres.2013.12.002PMID 24333835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• R: A language and environment for statistical computing.

  2014cited by this paper
• African Horse Sickness

  2013cited by this paper
• Ns1 Is a Key Protein in the Vaccine Composition to Protect Ifnar(−/−) Mice against Infection with Multiple Serotypes of African Horse Sickness Virus

  2013cited by this paper
• An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.

  2012cited by this paper
• Multiserotype Protection Elicited by a Combinatorial Prime-Boost Vaccination Strategy against Bluetongue Virus

  2012cited by this paper
• Structural Insight into African Horsesickness Virus Infection

  2012cited by this paper
• Virus-specific CD8⁺ T-cells detected in PBMC from horses vaccinated against African horse sickness virus.

  2012cited by this paper
• Detection of a Fourth Orbivirus Non-Structural Protein

  2011cited by this paper
• A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model

  2011cited by this paper
• Establishment of a Bluetongue Virus Infection Model in Mice that Are Deficient in the Alpha/Beta Interferon Receptor

  2009cited by this paper
• Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)

  2009cited by this paper
• Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.

  2009cited by this paper
• African horse sickness.

  2004cited by this paper
• Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries.

  2000cited by this paper
• Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus.

  1999cited by this paper
• Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.

  1996cited by this paper
• Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.

  1996cited by this paper
• Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.

  1996cited by this paper
• Identification of a linear neutralization domain in the protein VP2 of African horse sickness virus.

  1995cited by this paper
• Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine.

  1994cited by this paper
• African horse sickness virus structure.

  1994cited by this paper
• Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2.

  1993cited by this paper
• A comparison of the nucleotide sequences of cognate NS2 genes of three different orbiviruses.

  1991cited by this paper
• Observations on antibody levels associated with active and passive immunity to African horse sickness

  1988cited by this paper
• African horse-sickness killed-virus tissue culture vaccine.

  1966cited by this paper

• Development of African horse sickness disabled infectious single animal (DISA)-DIVA vaccine platform applied for all nine serotypes.

  2025cites this paper
• Development of an African horse sickness VP6 DIVA diagnostic ELISA

  2025cites this paper
• Cytokine mRNA Expression Profile in Target Organs of IFNAR (-/-) Mice Infected with African Horse Sickness Virus

  2024cites this paper
• The Potential of Plant-Produced Virus-like Particle Vaccines for African Horse Sickness and Other Equine Orbiviruses

  2024cites this paper
• Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice

  2024cites this paper
• Pathological features of African horse sickness virus infection in IFNAR−/− mice

  2023cites this paper
• Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice.

  2022cites this paper
• Recombinant Modified Vaccinia Virus Ankara Development to Express VP2, NS1, and VP7 Proteins of Bluetongue Virus.

  2022cites this paper
• African horse sickness in Thailand: Challenges of controlling an outbreak by vaccination

  2020cites this paper
• Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design

  2020influential citation
• African Horse Sickness: A Review of Current Understanding and Vaccine Development

  2019cites this paper
• Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor

  2019cites this paper
• A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model

  2018cites this paper
• African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.

  2018cites this paper
• The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host

  2018cites this paper
• Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness.

  2018cites this paper
• Strategies to obtain multiple recombinant modified vaccinia Ankara vectors. Applications to influenza vaccines.

  2018cites this paper
• Immunoinformatics Prediction of Peptide-Based Vaccine Against AfricanHorse Sickness Virus

  2017cites this paper
• Desarrollo de vacunas recombinantes marcadoras multiserotipo frente al virus de la lengua azul

  2017influential citation
• B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera

  2017cites this paper
• Immunogenicity of plant‐produced African horse sickness virus‐like particles: implications for a novel vaccine

  2017cites this paper
• Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.

  2017cites this paper
• Immune gene expression profiling of PBMC isolated from horses vaccinated with attenuated African horsesickness virus serotype 4.

  2016cites this paper
• Generation of Recombinant Modified Vaccinia Virus Ankara Encoding VP2, NS1, and VP7 Proteins of Bluetongue Virus.

  2016cites this paper
• African horse sickness virus serotype 4 antigens, VP1-1, VP2-2, VP4, VP7 and NS3, induce cytotoxic T cell responses in vitro.

  2016cites this paper
• VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV

  2015cites this paper
• Identification of CD8 T cell epitopes in VP2 and NS1 proteins of African horse sickness virus in IFNAR(-/-) mice.

  2015cites this paper
• Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge

  2015influential citation
• Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge

  2014cites this paper
• A Synthetic Biology Approach for a Vaccine Platform against Known and Newly Emerging Serotypes of Bluetongue Virus

  2014cites this paper
• Study of the virulence of serotypes 4 and 9 of African horse sickness virus in IFNAR(-/-), Balb/C and 129 Sv/Ev mice.

  2014cites this paper
• Against Known and Newly Emerging 1 Serotypes of Bluetongue Virus 2 3

  2014cites this paper